Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 18/20 | 0.38 |
| ▸ | RXRB | P28702 | 2/20 | 0.36 |
| ▸ | RXRG | P48443 | 2/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4134528 | 0.89 | TSHR (0.41) | RXRARXRBRXRGPPARG | |
| SCHEMBL4139264 | 0.86 | HRH4 (0.40) | RXRARXRBRXRGPPARG | |
| SCHEMBL4136167 | 0.86 | HRH4 (0.40) | RXRARXRBRXRGPPARG | |
| Hydrochloric Acid SCHEMBL4144352 | 0.86 | HRH4 (0.40) | RXRARXRBRXRGPPARG | |
| SCHEMBL3123416 | 0.84 | RXRA (0.44) | RXRARXRBRXRGPPARGPDE4A | |
| SCHEMBL3129586 | 0.79 | PDE4A (0.45) | RXRARXRBRXRGPPARGPDE4A | |
| SCHEMBL4143664 | 0.78 | TSHR (0.41) | RXRA | |
| SCHEMBL3133721 | 0.78 | RXRA (0.41) | RXRARXRBRXRGPDE4A | |
| SCHEMBL4131770 | 0.77 | HRH4 (0.34) | RXRARXRBRXRGPPARGPDE4A | |
| SCHEMBL3131213 | 0.77 | RXRA (0.50) | RXRARXRBRXRGPPARGPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118270-A1 | PHOSPHODIESTERASE 4 INHIBITORS | TALAMAS FRANCISCO XAVIER | 2009-05-07 | — | — | US | claimed |
| EP-1888528-A2 | PHOSPHODIESTERASE 4 INHIBITORS | Memory Pharmaceuticals Corporation (US) | 2008-02-20 | — | — | EP | claimed |
| US-20070049611-A1 | Phosphodiesterase 4 inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-01 | — | — | US | claimed |
| WO-2006135828-A2 | TRISUBSTITUTED AMINES AS PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2006-12-21 | — | — | WO | claimed |
| US-20090118270-A1 | PHOSPHODIESTERASE 4 INHIBITORS | TALAMAS FRANCISCO XAVIER | 2009-05-07 | — | — | US | disclosed |
| US-20090118270-A1 | PHOSPHODIESTERASE 4 INHIBITORS | TALAMAS FRANCISCO XAVIER | 2009-05-07 | — | — | US | disclosed |
| US-20090118270-A1 | PHOSPHODIESTERASE 4 INHIBITORS | TALAMAS FRANCISCO XAVIER | 2009-05-07 | — | — | US | disclosed |
| EP-1888528-A2 | PHOSPHODIESTERASE 4 INHIBITORS | Memory Pharmaceuticals Corporation (US) | 2008-02-20 | — | — | EP | disclosed |
| US-20070049611-A1 | Phosphodiesterase 4 inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-01 | — | — | US | disclosed |
| US-20070049611-A1 | Phosphodiesterase 4 inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-01 | — | — | US | disclosed |
| US-20070049611-A1 | Phosphodiesterase 4 inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-01 | — | — | US | disclosed |
| WO-2006135828-A2 | TRISUBSTITUTED AMINES AS PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2006-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049611-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE3B, PDE4B | RXRA 3125/4885RXRB 2549/4885RXRG 2640/4885 |
| US-20090118270-A1 | PHOSPHODIESTERASE 4 INHIBITORS | PDE4A, PDE3B, PDE4B | RXRA 3125/4885RXRB 2549/4885RXRG 2640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.